During the past decade, CH Carcassonne conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CH Carcassonne" #1 sponsor was "Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer" with 2 trials, followed by "Federation Francophone de Cancerologie Digestive" with 2 trials sponsored, "Hospira, now a wholly owned subsidiary of Pfizer" with 2 trials sponsored, "ARCAGY/ GINECO GROUP" with 1 trials sponsored and "Groupe Francophone des Myelodysplasies" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CH Carcassonne" #1 collaborator was "AstraZeneca" with 2 trials as a collaborator, "Celgene" with 1 trials as a collaborator, "Centre Hospitalier Universitaire de Saint Etienne" with 1 trials as a collaborator, "GORTEC" with 1 trials as a collaborator and "Investigation network on venous thrombo-embolism" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "CH Carcassonne" are "Deep Vein Thrombosis" (2 trials), "Arthritis, Rheumatoid" (1 trials), "Chemotherapy-induced Anemia" (1 trials), "Chemotherapy-induced Febrile Neutropenia (FN)" (1 trials) and "Epithelial Ovarian Cancer" (1 trials). Many other conditions were trialed in "CH Carcassonne" in a lesser frequency.

Most popular intervention types in "CH Carcassonne" are "Drug" (5 trials), "Other" (3 trials), "Biological" (1 trials), "Diagnostic Test" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "FOLFIRI Protocol" (2 trials), "Aflibercept" (1 trials), "Avelumab" (1 trials), "Bevacizumab" (1 trials) and "Cetuximab" (1 trials). Other intervention names were less common.

The vast majority of trials in "CH Carcassonne" are 12 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "CH Carcassonne". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in CH Carcassonne, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in CH Carcassonne, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".

CH Carcassonne has several departments that took part in Clinical trials: "Ch Antoine Gayraud; Oncologie" - 4 trials